| A297 |
Abituzumab Biosimilar（Anti-Integrin aV / ITGAV / CD51 Reference Antibody）
Featured
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer. |
|
| A298 |
Intetumumab Biosimilar（Anti-Integrin aV / ITGAV / CD51 Reference Antibody）
Featured
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer. |
|
| A299 |
Tadocizumab Biosimilar（Anti-Integrin a2b3 (ITGA2 & ITGB3) Reference Antibody）
Featured
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. |
|
| A300 |
OS2966 Biosimilar（Anti-Integrin b1 / ITGB1 / CD29 Reference Antibody）
Featured
|
|
|
| A301 |
Erlizumab Biosimilar（Anti-Integrin b2 / ITGB2 / CD18 Reference Antibody）
Featured
|
|
|
| A302 |
Genentech patent anti-Integrin β7 Biosimilar（Anti-Integrin b7 / ITGB7 Reference Antibody）
Featured
|
|
|
| A303 |
ADCT-901 Biosimilar（Anti-KAAG1 Reference Antibody）
Featured
|
|
|
| A304 |
ADCT-901-MMAE Biosimilar(Anti-KAAG1 Reference Antibody)
Featured
|
|
|
| A305 |
Macrogenics patent anti-KID3 Biosimilar(Anti-KID3 Reference Antibody)
Featured
|
|
|
| A306 |
Lirilumab Biosimilar(Anti-KIR Reference Antibody)
Featured
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. |
|
| A307 |
Innate patent anti-KIR2DL Biosimilar(Anti-KIR2DL1 / CD158a Reference Antibody)
Featured
|
|
|
| A308 |
Lacutamab Biosimilar(Anti-KIR3DL2 / CD158k Reference Antibody)
Featured
|
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma. |
|
| A309 |
JNJ-69086420 Biosimilar(Anti-KLK2 / Kallikrein 2 Reference Antibody)
Featured
|
|
|
| A310 |
Genentech patent anti-KLK5 Biosimilar(Anti-KLK5 / Kallikrein 5 Reference Antibody )
Featured
|
|
|
| A311 |
NGM313 Biosimilar(Anti-Klotho Beta Reference Antibody)
Featured
|
|
|
| A312 |
RG7992 Biosimilar(Anti-Klotho Beta Reference Antibody)
Featured
|
|
|
| A313 |
Fianlimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. |
|
| A314 |
Favezelimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902). |
|
| A315 |
Ieramilimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. |
|
| A316 |
Encelimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft). |
|
| A317 |
Relatlimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer. |
|
| A318 |
Miptenalimab Biosimilar(Anti-LAG3 / CD223 Reference Antibody)
Featured
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II. |
|
| A319 |
SAR428926 Biosimilar(Anti-LAMP1 / CD107a Reference Antibody)
Featured
|
|
|
| A320 |
Brigham and Womens anti-LAP Biosimilar(Anti-LAP Reference Antibody)
Featured
|
|
|
| A321 |
Mibavademab Biosimilar(Anti-LEPR / CD295 Reference Antibody)
Featured
|
|
|
| A322 |
MB-311 Biosimilar(Anti-Lewis Y Reference Antibody)
Featured
|
|
|
| A323 |
MSC-1 Biosimilar(Anti-LIF Reference Antibody)
Featured
|
|
|
| DC66946 |
Patulin
Featured
|
Patulin (Terinin) is a mycotoxin produced by fungi including the Aspergillus, Penicillium, and Byssochlamys species, causes chromosome breakage, mutation, teratogenic and cytotoxic. Patulin induces autophagy-dependent apoptosis through lysosomal-mitochondrial axis, and causes DNA damage. |
|
| A324 |
Polzastobart Biosimilar（Anti-LILRB2 / ILT4 / CD85d Reference Antibody）
Featured
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor. |
|
| A325 |
Merck patent anti-ILT3 complex Biosimilar（Anti-LILRB4 / ILT3 / CD85k Reference Antibody）
Featured
|
|
|
